Early this year, the collaboration of the Philippine Heart Association, the Philippine Lipid and Atherosclerosis Society, and the Philippine Society of Endocrinology, Diabetes, and Metabolism provided us an update on the 2005’s local Clinical Practice Guidelines for the Management of Dyslipidemia. The update answered applicability issues of the different prevailing dyslipidemia guidelines from the different acclaimed international societies such as the ACC/ AHA, ESC etc.
highlights in the field of cardiology is the HOPE 3 trial. The results were based on a healthy population, with at least one CV risk factor, followed up for a median of 5.6 years. It used a 2×2 factorial design, daily rosuvastatin or placebo, plus daily candesartan/hydrochlorothiazide or placebo, to assess the safety and efficacy of cholesterol lowering, blood pressure (BP) lowering, or both.